from
http://journals.lww.com/neurotodayon...spx?PostID=383
Monday, October 06, 2014
Monthly Daclizumab Found Superior to Interferon Beta-1a for Relapsing-Remitting MS
by Richard Robinson
BOSTON — The monoclonal antibody daclizumab was found to be superior to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (MS) in one of the largest head-to-head trials ever conducted in MS.
The data showed that daclizumab, given once monthly for up to three years, provided better clinical, imaging, and subjective outcomes, albeit with more cutaneous side effects but an otherwise similar safety profile.
Lead investigator Ludwig Kappos, MD, professor and chair of the departments of neurology and biomedicine at University Hospital in Basel, Switzerland, presented the findings in September at the joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
**Post shortened by moderator in order to conserve space. Please click on link provided**
http://journals.lww.com/neurotodayon...spx?PostID=383
Monday, October 06, 2014
Monthly Daclizumab Found Superior to Interferon Beta-1a for Relapsing-Remitting MS
by Richard Robinson
BOSTON — The monoclonal antibody daclizumab was found to be superior to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (MS) in one of the largest head-to-head trials ever conducted in MS.
The data showed that daclizumab, given once monthly for up to three years, provided better clinical, imaging, and subjective outcomes, albeit with more cutaneous side effects but an otherwise similar safety profile.
Lead investigator Ludwig Kappos, MD, professor and chair of the departments of neurology and biomedicine at University Hospital in Basel, Switzerland, presented the findings in September at the joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
**Post shortened by moderator in order to conserve space. Please click on link provided**